» Articles » PMID: 15771565

TNF/TNFR Family Members in Costimulation of T Cell Responses

Overview
Date 2005 Mar 18
PMID 15771565
Citations 584
Authors
Affiliations
Soon will be listed here.
Abstract

Several members of the tumor necrosis factor receptor (TNFR) family function after initial T cell activation to sustain T cell responses. This review focuses on CD27, 4-1BB (CD137), OX40 (CD134), HVEM, CD30, and GITR, all of which can have costimulatory effects on T cells. The effects of these costimulatory TNFR family members can often be functionally, temporally, or spatially segregated from those of CD28 and from each other. The sequential and transient regulation of T cell activation/survival signals by different costimulators may function to allow longevity of the response while maintaining tight control of T cell survival. Depending on the disease condition, stimulation via costimulatory TNF family members can exacerbate or ameliorate disease. Despite these complexities, stimulation or blockade of TNFR family costimulators shows promise for several therapeutic applications, including cancer, infectious disease, transplantation, and autoimmunity.

Citing Articles

Distinct immunological features of oropharyngeal cancer peritumoral tonsillar tissues from inflammatory tonsils and regional lymph nodes: A pilot study.

Wakisaka N, Moriyama-Kita M, Kondo S, Kobayashi E, Ueno T, Nakanishi Y PLoS One. 2025; 20(1):e0316102.

PMID: 39820810 PMC: 11737673. DOI: 10.1371/journal.pone.0316102.


Chemical-Specific T Cell Tests Aim to Bridge a Gap in Skin Sensitization Evaluation.

Fritsch N, Aparicio-Soto M, Curato C, Riedel F, Thierse H, Luch A Toxics. 2024; 12(11).

PMID: 39590982 PMC: 11598016. DOI: 10.3390/toxics12110802.


TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.

Vredevoogd D, Apriamashvili G, Levy P, Sinha S, Huinen Z, Visser N J Immunother Cancer. 2024; 12(11).

PMID: 39510795 PMC: 11552591. DOI: 10.1136/jitc-2024-010145.


Necroptosis-based glioblastoma prognostic subtypes: implications for TME remodeling and therapy response.

Khan M, Huang X, Ye X, Zhang D, Wang B, Xu A Ann Med. 2024; 56(1):2405079.

PMID: 39387496 PMC: 11469424. DOI: 10.1080/07853890.2024.2405079.


Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy.

Fang M, Allen A, Luo C, Finn J Front Immunol. 2024; 15:1457629.

PMID: 39281684 PMC: 11392856. DOI: 10.3389/fimmu.2024.1457629.